MEA Non-Invasive Prenatal Testing Market

MEA Non-Invasive Prenatal Testing Market Size (2023 to 2028)

The size of the Middle East & Africa Non-Invasive Prenatal Testing Market was valued at USD 0.13 Billion in 2023. It is further projected to be growing at a CAGR of 4.93%, to touch USD 0.16 billion by 2028.

The presence of multiple large-scale enterprises, for instance, will have a beneficial impact on the market's growth in this region during the forecast period. In addition, the increased prevalence of genetic abnormalities, rapid adoption of next-generation sequencing, new product introductions, an increased number of non-invasive prenatal testing service providers are further promoting the NIPT market in the Middle East and Africa. Furthermore, the rising number of stillbirths in the Middle East and Africa is likely to provide a significant growing opportunity for early illness detection, which is expected to favor the market in the coming future.

Furthermore, the advantages of non-invasive prenatal testing over conventional prenatal tests, such as their non-invasive nature, higher accuracy, and shorter procedure time, are expected to accelerate the growth of the NIPT market in the Middle East and Africa during the forecast period. In addition, the expansion of the market in this region is expected to be fueled by innovations in existing tests in terms of advanced functionality, improved chemistry, and bioinformatics analysis. Furthermore, one of the market's main driving forces is the improvement of payment policies for ordinary and low-risk pregnancies.

However, a lack of test accessibility in emerging nations, ethical issues, and rigorous government regulations are only a few factors that limit the Middle East and Africa NIPT market growth.

This research report on the Middle East and Africa non-invasive prenatal testing market has been segmented and sub-segmented into the following categories.

By Instruments: 

• Ultrasound
• NGS
• PCR
• Microarray

By Method: 

• FCMB
• Cf-DNA

By Application: 

• Trisomy
• Microdeletion
• Genetics
• Rh Factor

By End User: 

• Hospitals
• Diagnostic Labs

By Country: 

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

In terms of revenue share, the Middle East and Africa had a middle part of the global market in 2021. The Middle East and Africa Non-Invasive Prenatal Testing market are expected to rise healthily during the forecast period. The presence of important companies, a large number of research activities, and a highly structured healthcare market drive the market in the region.

Increased investment by key players in the Middle East and Africa and rising maternal age are expected to drive the market for non-invasive prenatal testing in the Middle East and Africa. As a result, the country is expected to be the most attractive market for non-invasive prenatal testing, with a high attractiveness index, due to the early adoption of technology.

Furthermore, the rising acceptance rate for prenatal testing and increased health consciousness and understanding among the general public about the benefits and significance of such testing are influencing the regional market growth.

Other genetic diseases, such as spina bifida, cleft palate, and sickle cell anemia, are being diagnosed and treated in the early stages of embryonic development in countries like the UAE and Kuwait by healthcare providers and expecting parents. Furthermore, the changing trend toward childbearing at a young age for the mother has a beneficial impact on regional market growth.

Increasing maternal age can contribute to various health issues, including high blood pressure, decreased fertility, an increased risk of miscarriage, and an increased risk of genetic abnormalities in the fetus.

KEY MARKET PLAYERS:

Companies playing an active role in the MEA non-invasive prenatal testing market profiled in the report are GE Healthcare (U.S.), Koninklijke Philips N.V. (Netherlands), Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Pacific Biosciences of California, Inc. (U.S.), PerkinElmer, Inc. (U.S.), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (U.S.), and Beijing Genomics Institute (China).